SUPPLEMENT
Q1 2026 — Investor materials
Q1 2026PDF · 6 pages454 KB
March 23, 2026 2026 Q1 Economic Factors and J&J Announcements Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well as public commentary made by management during the quarter and recent earnings calls. Any additional information included herein is provided as phasing considerations and should not be construed as guidance. Phasing considerations: As a reminder, please note the following: • The impact of Stelara erosion in Q1 2025 was less pronounced. • In 2026, we benefit from a 53 rd week in our financial calendar, which is worth approximately 100 basis points to full year sales growth and neutral to bottom line due to expenses for an additional week. • We expect heavy investment in Q1 2026 compared to the rest of the year. • For your convenience, as we progress through 2026, we have attached QTD and FY segment P&Ls for 2025. Macro-economic factors: • Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as well as interest income on our cash position. • Tariffs: In Q4 we noted a 2026 approximate impact of $500MM, exclusively related to our MedTech business, based on tariff information known at the time. We are reviewing the impact of the Supreme Court’s decision to deny the IEEPA tariff authority as well as the implementation of new tariffs through Section 122 at a flat 10%. We will provide further guidance as we have additional clarity on the financial impact of these decisions and will continue to monitor tariffs and their potential impact to our business. • Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to experience, impacts to the Company's business resulting from the Russia-Ukraine war, conflict in the Middle East as well as increasing tensions between the U.S. and China. -- 1 of 6 -- • Foreign Exchange: We do not offer guidance or predictions on currency movements, but as highlighted by Joe during the Q4 2025 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar as of mid-January of 1.17 to give a sense of the potential impact on Full Year 2026 guidance. The Euro Spot Rate averaged 1.17 in January, 1.18 in February, compared to a current spot rate of approximately 1.15 this past week. As a reminder, our results are based on a basket of currencies, of which, not all align to the Euro. Conference participation J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for the events below have been attached for your convenience. • J.P. Morgan 44th Annual Healthcare Conference: Joaquin Duato – Chairman of the Board, Chief Executive Officer, fireside chat with Christopher Schott - JPMorgan Chase & Co - Analyst • TD Cowen 46th Annual Health Care Conference: Joseph Wolk – Chief Financial Officer, Executive Vice President, fireside chat with Joshua Jennings - Cowen and Company LLC - Analyst • Barclays 28th Annual Global Healthcare Conference: Hani Abouhalka – Company Group Chair, Surgery, MedTech, fireside chat with Matt Miksic – Barclays Services Corp - Analyst -- 2 of 6 -- Announcements Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom, and MedTech News & Events page. • M&A: N/A • Talc: please visit factsabouttalc.com for the latest company statements • Enterprise: Next Generation Cell Therapy Manufacturing Facility; Agreement with U.S. Government to Improve Access • Innovative Medicine: o CAPLYTA: Phase 3 data o Erda-iDRS: Phase 1 Study o ERLEADA: Head-to-Head analysis compares overall survival outcomes of ERLEADA o ICOTYDE: FDA Approval o IMAAVY: FDA Submission o Nipocalimab: U.S. FDA Fast Track designation; Phase 2b JASMINE study o Pasritamig: Early study results o RYBREVANT: Phase 1b/2 OrigAMI-1 study o RYBREVANT FASPRO: Phase 1b/2 OrigAMI-4 study; U.S. FDA Breakthrough Therapy Designation; FDA Approval- EGFR-targeted therapy o TECVAYLI: Phase 3 MajesTEC-9 study o TECVAYLI & DARZALEX FASPRO: FDA Approval; Quadruplet regimen approved in the U.S.; European Medicines Agency Submission o TREMFYA: QUASAR long-term extension (LTE) study • MedTech: o EP: OMNYPULSE OMNY-AF Pilot Study at 2026 AF Symposium o Surgery: OTTAVA FDA Submission o Vision: FDA Approval of TECNIS PureSee Intraocular Lens -- 3 of 6 -- J&J earnings calls: • Q4 2025 earnings call: Full year 2026 Operational Sales Guidance of $99.5B - $100.5B or 5.7% - 6.7% and Adjusted Operational Earnings Per Share of $11.28 - $11.48 or 4.5% - 6.5% was provided on our Q4 2025 Earnings Call. For your convenience, the final Q4 2025 earnings transcript and presentation are attached. Full Q4 2025 earnings call operational commentary and key drivers can be listened to here and the Q4 2025 10-K can be found here. • Q1 2025 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth rates for Q1 2025. Full Q1 2025 operational commentary, key drivers, and one-timers can be listened to here and the Q1 2025 10-Q can be found here. For your convenience, the final Q1 2025 earnings transcript and presentation are attached. Q1 2025: o Enterprise: $21.9B, 4.2% operational sales growth and 3.3% adjusted operational sales growth Enterprise sales highlights can be found on page 6 of the final Q1 2025 earnings transcript attached P&L highlights can be found on page 7 of the final Q1 2025 earnings transcript attached o Innovative Medicine: $13.9B, 4.2% operational sales growth Innovative Medicine sales highlights can be found on page 6 of the final Q1 2025 earnings transcript attached o MedTech: $8.0B, 4.1% operational sales growth MedTech sales highlights can be found on page 6-7 of the final Q1 2025 earnings transcript attached -- 4 of 6 -- 1 Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 2025 (Unaudited; Dollar in millions) Earnings before provision for taxes on income by segment 1 Innovative Medicine Amount % to Sales Amount % to Sales Amount % to Sale s Amount % to Sales Amount % to Sales Sales to customers $1 3,873 1 00.0 $1 5,202 1 00.0 $1 5,563 1 00.0 $1 5,763 1 00.0 $60,401 1 00.0 Cost of products sold (COGS) 4,020 29.0 3,978 26.2 3,672 23.6 3,976 25.2 1 5,646 25.9 Selling, marketing and administrative expenses (SM&A) 2,261 1 6.3 2,789 1 8.3 2,869 1 8.5 3,456 21 .9 1 1 ,375 1 8.8 Research and development expense (R&D)* 2,548 1 8.4 2,869 1 8.9 2,944 1 8.9 3,466 22.0 1 1 ,827 1 9.6 Other segment items 1 (1 66) (1 .2) 1 4 0.1 (368) (2.4) (1 93) (1 .2) (71 3) (1 .2) Adjusted segment income before tax 2 $5,21 0 37.5 $5,552 36.5 $6,446 41 .4 $5,058 32.1 $22,266 36.9 Amount % to Sales Amount % to Sales Amount % to Sale s Amount % to Sales Amount % to Sales Sales to customers $1 3,873 1 00.0 $1 5,202 1 00.0 $1 5,563 1 00.0 $1 5,763 1 00.0 $60,401 1 00.0 Cost of products sold (COGS) 3,371 24.3 3,1 80 20.9 3,093 1 9.9 3,261 20.7 1 2,905 21 .4 Selling, marketing and administrative expenses (SM&A) 2,261 1 6.3 2,789 1 8.3 2,869 1 8.4 3,456 21 .9 1 1 ,375 1 8.8 Research and development expense (R&D)* 2,548 1 8.4 2,869 1 8.9 2,944 1 8.9 3,466 22.0 1 1 ,827 1 9.6 Other segment items 1 (204) (1 .5) (1 29) (0.8) (238) (1 .5) (1 35) (0.9) (706) (1 .2) Adjusted segment income before tax 2 $5,897 42.5 $6,493 42.7 $6,895 44.3 $5,71 5 36.3 $25,000 41 .4 As reported Q1 Q2 Q3 Q4 YTD Adjusted Q1 Q2 Q3 Q4 YTD -- 5 of 6 -- 1 Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 2025 (Unaudited; Dollar in millions) Earnings before provision for taxes on income by segment 2 MedTech Amount % to Sale s Amount % to Sales Amount % to Sales Amount % to Sales Amount % to Sales Sales to customers $8,020 1 00.0 $8,541 1 00.0 $8,430 1 00.0 $8,801 1 00.0 $33,792 1 00.0 Cost of products sold (COGS) 3,326 41 .5 3,638 42.6 3,61 2 42.9 3,973 45.1 1 4,549 43.1 Selling, marketing and administrative expenses (SM&A) 2,656 33.1 2,862 33.5 2,801 33.2 3,035 34.5 1 1 ,354 33.6 Research and development expense (R&D)* 677 8.4 647 7.6 728 8.6 786 8.9 2,838 8.4 Other segment items 1 (60) (0.7) 1 90 2.2 2 - 806 9.2 938 2.8 Adjusted segment income before tax 2 $1 ,421 1 7.7 $1 ,204 1 4.1 $1 ,287 1 5.3 $201 2.3 $4,1 1 3 1 2.1 Amount % to Sale s Amount % to Sales Amount % to Sales Amount % to Sales Amount % to Sales Sales to customers $8,020 1 00.0 $8,541 1 00.0 $8,430 1 00.0 $8,801 1 00.0 $33,792 1 00.0 Cost of products sold (COGS) 2,795 34.8 3,1 42 36.8 3,1 1 9 37.0 3,435 39.0 1 2,491 37.0 Selling, marketing and administrative expenses (SM&A) 2,656 33.1 2,862 33.5 2,801 33.2 3,035 34.5 1 1 ,354 33.6 Research and development expense (R&D)* 671 8.4 690 8.1 728 8.6 786 8.9 2,875 8.5 Other segment items 1 (1 82) (2.2) (53) (0.6) 1 5 0.2 1 0 0.2 (21 0) (0.6) Adjusted segment income before tax 2 $2,080 25.9 $1 ,900 22.2 $1 ,767 21 .0 $1 ,535 1 7.4 $7,282 21 .5 As reported Q1 YTD Adjusted Q1 YTD Q2 Q2 Q3 Q3 Q4 Q4 -- 6 of 6 --